Mirati Therapeutics` Mocetinostat Included In Stand Up To Cancer`s Cutting-Edge Clinical Trial Initiative For NSCLC Patients
(World News Science)

SAN DIEGO, Oct. 12, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage oncology biotechnology company, announced today that the Company has been included in the SU2C Catalyst program, a cutting-edge research initiative led by Stand Up To Cancer (SU2C) designed to bring innovative cancer treatments to patients quickly through novel collaborations between industry and academia. A clinical trial research grant has been awarded to the Van Andel Research Institute (Grand Rapids, Michigan) to evaluate the potential of epigenetic agents to improve patient responses to immunotherapy in non-small cell lung cancer (NSCLC). The $2.5 million research grant will support a...